Association of IBRAF/I V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer

The early identification of aggressive forms of cancer is of high importance in treating papillary thyroid cancer (PTC). Disease dissemination is a major factor influencing patient survival. Mutation status of BRAF oncogene, BRAF V600E, is proposed to be an indicator of disease recurrence; however,...

Full description

Saved in:
Bibliographic Details
Published inBiomedicines Vol. 12; no. 3
Main Authors Blazekovic, Ivan, Samija, Ivan, Perisa, Josipa, Gall Troselj, Koraljka, Regovic Dzombeta, Tihana, Radulovic, Petra, Romic, Matija, Granic, Roko, Sisko Markos, Ines, Frobe, Ana, Kusic, Zvonko, Jukic, Tomislav
Format Journal Article
LanguageEnglish
Published MDPI AG 01.02.2024
Subjects
Analysis
Cancer
Care and treatment
Diseases
Gene mutations
Immunohistochemistry
Medical research
Medicine, Experimental
Relapse
Thyroid cancer
Croatia
Online AccessGet full text

Cover

More Information
Summary:The early identification of aggressive forms of cancer is of high importance in treating papillary thyroid cancer (PTC). Disease dissemination is a major factor influencing patient survival. Mutation status of BRAF oncogene, BRAF V600E, is proposed to be an indicator of disease recurrence; however, its influence on PTC dissemination has not been deciphered. This study aimed to explore the association of the frequency of BRAF V600E alleles in PTC with disease dissemination. In this study, 173 PTC samples were analyzed, measuring the proportion of BRAF V600E alleles by qPCR, which was then normalized against the proportion of tumor cells. Semiquantitative analysis of BRAF V600E mutant protein was performed by immunohistochemistry. The BRAF V600E mutation was present in 60% of samples, while the normalized frequency of mutated BRAF alleles ranged from 1.55% to 92.06%. There was no significant association between the presence and/or proportion of the BRAF V600E mutation with the degree of PTC dissemination. However, the presence of the BRAF mutation was significantly linked with angioinvasion. This study’s results suggest that there is a heterogeneous distribution of the BRAF mutation and the presence of oligoclonal forms of PTC. It is likely that the BRAF mutation alone does not significantly contribute to PTC aggressiveness.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines12030477